Literature DB >> 8098345

Leukemic T cells from patients with cutaneous T-cell lymphoma demonstrate enhanced activation through CDw60, CD2, and CD28 relative to activation through the T-cell antigen receptor complex.

E R Hansen1, G L Vejlsgaard, K D Cooper, M Heidenheim, J K Larsen, V C Ho, C W Ross, D A Fox, K Thomsen, O Baadsgaard.   

Abstract

Antigen-dependent activation of T cells occurs through the T-cell antigen-receptor complex (TCR/CD3). Antigen-independent T-cell activation may occur through the surface molecules CDw60, CD2, and CD28. We wished to determine whether these antigen-independent T-cell-activation pathways could be involved in proliferation of leukemic T cells from patients with cutaneous T-cell lymphoma (CTCL). Whereas CDw60 was only expressed on 28% +/- 7% (mean +/- SEM) of blood T cells obtained from healthy control subjects (n = 4), CDw60 was expressed on 94% +/- 3% of blood T cells obtained from patients with CTCL (n = 4). Dual color immunofluorescence microscopy of the T-cell infiltrate in involved skin of these patients demonstrated that almost 100% of the T cells expressed CDw60. Not only did T cells in the patients with CTCL express CDw60, but triggering of the T cells with anti-CDw60 resulted in enhanced proliferation relative to anti-TCR/CD3 and mitogenic lectins. Other antigen-independent pathways also appeared highly active in the T cells from patients with CTCL because enhanced proliferation relative to anti-TCR/CD3 or mitogenic lectins was found when anti-CD2 or anti-CD28 plus phorbol ester was used as stimulant. Despite the brisk proliferation induced by anti-CDw60, anti-CD2, or anti-CD28, T cells from the patients did not produce detectable amounts of gamma-interferon. The inability to produce gamma-interferon correlates with our finding of absent (n = 3) or weak (n = 1) intercellular adhesion molecule-1 expression in the lesional keratinocytes in these patients. In conclusion, T cells of patients with CTCL demonstrate elevated expression of a T-cell-independent signaling molecule CDw60 and respond to antigen-independent activating signals.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8098345     DOI: 10.1111/1523-1747.ep12472333

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  Lesional psoriatic T cells contain the capacity to induce a T cell activation molecule CDw60 on normal keratinocytes.

Authors:  L Skov; L S Chan; D A Fox; J K Larsen; J J Voorhees; K D Cooper; O Baadsgaard
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

2.  CDw60: an antigen expressed in many normal tissues and in some tumours.

Authors:  A Gocht; A Gadatsch; G Rutter; B Kniep
Journal:  Histochem J       Date:  2000-07

3.  The role of immune checkpoint receptors in the malignant phenotype of cutaneous T cell lymphoma.

Authors:  Rony Shreberk-Hassidim; Anat Geiger-Maor; Galit Eisenberg; Sharon Merims; Emma Hajaj; Jonathan E Cohen; Shiri Klein; Shoshana Frankenburg; Lilach Moyal; Emilia Hodak; Abraham Zlotogorski; Michal Lotem
Journal:  Immunol Res       Date:  2022-07-22       Impact factor: 4.505

4.  9-O-Acetylation of sialomucins: a novel marker of murine CD4 T cells that is regulated during maturation and activation.

Authors:  M Krishna; A Varki
Journal:  J Exp Med       Date:  1997-06-02       Impact factor: 14.307

5.  Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma.

Authors:  B N Lee; M Duvic; C K Tang; C Bueso-Ramos; Z Estrov; J M Reuben
Journal:  Clin Diagn Lab Immunol       Date:  1999-01

6.  Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides.

Authors:  Benjamin F Chong; Adam J Wilson; Heather M Gibson; Mikehl S Hafner; Yu Luo; Carrie J Hedgcock; Henry K Wong
Journal:  Clin Cancer Res       Date:  2008-02-01       Impact factor: 12.531

7.  CDw60: a marker for human CD8+ T helper cells.

Authors:  E P Rieber; G Rank
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.